Titles Medical director, Pediatric Dermatology and Dermatology, Birthmarks and Vascular Anomalies Center, Children's Hospital of Wisconsin; professor, Dermatology and Pediatrics; vice chair, Department of Dermatology Medical College of Wisconsin.
Study interests Hemangioma, infantile Hemangioma, vascular anomalies, venous malformation.
Education Medical degree, Loyola University, Chicago, 1991; internship, Medicine, University of Colorado, Denver, 1992; residency, Dermatology, Medical College of Wisconsin, Milwaukee, 1995; fellowship, Clinical Research and Pediatric Dermatology, Medical College of Wisconsin, Milwaukee, 1996.
Video Profile Meet Dr. Drolet and learn about the Birthmarks & Vascular Anomalies Center at Children's Hospital of Wisconsin by watching the following video:
Certifications American Board of Dermatology, Pediatric Dermatology.
Honors Loyola University Student Research Fellowship; Alpha Omega Alpha, 1991; Best Doctors in Milwaukee (Milwaukee Magazine) 2004, 2006, 2007, 2008, 2009, 2010; Society for Pediatric Dermatology Research Award, 2006; Small Business Times Health Care Hero Award, 2006; Executive Leadership in Academic Medicine (ELAM) Fellowship, 2008.
Representative publications
Drolet BA, Swanson E, Frieden IJ. Infantile Hemangiomas: An Emerging Health Issue Linked to an Increasing rate of Low Birth Weight Infants in the United States. Journal Pediatrics. 2008; 153:712-715.
Holland KE, Frieden IJ, Wyatt D, Frommelt PC, Drolet BA. Hypoglycemia in Children Taking Propranolol for the Treatment of Infantile Hemangiomas. Arch Dermatol. 2010; 146:775-778.
Drolet BA, Chamlin SL, Garzon MC, Adams D, Baselga E, Haggstrom AN, Holland KE, Horii KA, Juern A, Lucky AW, Mancini AJ, McCuaig C, Metry DW, Morel KD, Newell BD, Nopper AJ, Powell J, Frieden IJ. Prospective Study of Spinal Anomalies in Children with Infantile Hemangiomas of the Lumbosacral Skin. Journal Pediatrics. 2010; 157:789-794.
Haggstrom AN, Garzon MC, Adams D, Baselga E, Chamlin SL, Frieden IJ, Holland K, Mancini AJ, MCCuaig C, Metry DW, Morel K, Lucky A, Powell J, Perkins S, Siegel E, Drolet BA. A Prospective Study Examining the Risk for PHACE Syndrome in Infants with Large Facial Hemangiomas. Pediatrics. 2010; 126:418-426.
Hess CP, Fullerton HJ, Metry DW, Siegel DH, Drolet BA, Auguste KI, Gupta N, Haggstrom AN, Frieden IJ, Barkovich AJ. Cervical and Intracranial Arterial Anomalies in 70 Patients with PHACE Syndrome: Neuroradiologic Findings and Proposed Pathogeneiss. Am Journal Neuroradiol. 2010, Aug. 12. [Epub ahead of print].
Kelly ME, Juern Am, Grossman WJ, Schauer DW, Drolet BA. Immunosuppressive Effects in Infants Treated with Oral Corticosteroids for Infantile Hemangiomas. Arch Dermatol. 2010; 146:767-774.
Grants
Phase II Clinical Trial Assessing Efficacy and Safety of Oral Prednisolone vs. Vincristine in the Treatment of Infantile Hemangiomas, Food and Drug Administration OPD Grant Program, 1/08-1/11, co-principal investigator.
Immune Suppression of Infants Treated with Oral Corticosteroids for Infantile Hemangiomas, Society for Pediatric Dermatology, 11/15/06-11/14/08, principal investigator.
Immune Suppression of Infants Treated with Oral Corticosteroids for Infantile Hemangiomas, Research Affairs Committee, Medical College of Wisconsin, 11/1/07-6/30/08, principal investigator.
Large Facial Hemangiomas and Associated Vascular Anomalies, Children's Research Institute, 2/15/05-13/31/07, principal investigator.
Multifocal Lymphangioendotheliomatosis with Thrombocytopenia, Children's Research Institute, principal investigator.
Prospective Cohort Study of Hemangiomas of Infancy, Spirit Foundation 10/03-12/08, principal investigator.
Phase II Clinical Trial Assessing Efficacy and Safety of Oral Prednisolone vs. Vincristine in the Treatment of Infantile Hemangiomas, Greater Milwaukee Foundation, 6/07-6/10, co-principal investigator.
Genomewide Association Study on Infantile Hemangiomas, Bleser Family Foundation (through Children's Hospital of Wisconsin Foundation), 12/06-12/09, principal investigator.
Genomewide Association Study on Infantile Hemangiomas, Keough Family Foundation (through Children's Hospital of Wisconsin Foundation), 12/06-12/09, principal investigator.
Phase II Clinical Trial Assessing Efficacy and Safety of Oral Prednisolone vs. Vincristine in the Treatment of Infantile Hemangiomas, Bleser Family Foundation (through Children's Hospital of Wisconsin Foundation), 12/07-12/10, co-principal investigator.
Food and Drug Administration OPD Grant Program, Phase II Clinical Trial Assessing Efficacy and Safety of Oral Prednisolone vs. Vincristine in the Treatment of Infantile Hemangiomas, 09/2007 - 09/2011, principal investigator.
NIH Challenge Grant, NIAMS, Severity Scale and Quality of Life Instrument for Infantile Hemangiomas, 09/2009 - 08/2011, co-investigator.
Greater Milwaukee Foundation, Phase II Clinical Trial Assessing Efficacy and Safety of Oral Prednisolone vs. Vincristine in the Treatment of Infantile Hemangiomas, 06/2007 - 09/2011, co-principal investigator.
Contact Children's Research Institute 8701 Watertown Plank Road Wauwatosa, WI 53226 Phone: (414) 955-2818 Fax: (414) 266-3315 E-mail: drolet@mcw.edu
Children's Hospital of Wisconsin in Milwaukee, serving Wisconsin, Northern Illinois and
Michigan's Upper Peninsula and beyond through nationally-recognized programs.
Titles
